Cash/Burn From SEC Filing For Period: 

Q1 '20

ESPR

Esperion

ESPERION is passionately committed to developing and commercializing oral, LDL-C lowering therapies for patients with hypercholesterolemia.

Cash

$157.3M

Burn Rate

-$78.2M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Bempedoic Acid (Nexletol)

Elevated LDL-C (not adequately controlled with statins)

Quarterly Sales (approved)

November 06, 2020 (Est)

Bempedoic Acid/ Ezetimibe (Nexlizet)

Hypercholesterolemia

Quarterly Sales (Approved)

November 06, 2020 (Est)

Recent Posts

See What The Community Is Saying - Click To See Full Post

ESPR - Q2 2020 Net Sales...

#ESPR reported Q2 2020 Financial Results. See our AmpCard for details. #ESPR, #Bempedoic_Acid, #Ezetimibe, #Nexlizet, #Nexletol
...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon